Trials / Completed
CompletedNCT02853903
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.
Detailed description
By enrolling patients with multiple kinds of solid tumor adapted to enrolled criteria, this study will document for the first time the short/long term efficacy of auto/allogenic NK cells.The outcome will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NK immunotherapy | Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v. |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
- First posted
- 2016-08-03
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02853903. Inclusion in this directory is not an endorsement.